DMF significantly reduced the annualized relapse rate beginning in weeks @-@ ( BID , P = @ ; TID , P = @ ) ; the proportion of patients relapsed beginning at week @ ( BID , P = @ ) and week @ ( TID , P = @ ) ; and the proportion of patients with @-week confirmed disability progression beginning at week @ ( BID , P = @ ) and week @ ( TID , P = @ ) , compared with placebo .